C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target?

The COVID-19 Pandemic: Is It A Wolf Consuming Fertility?

Protein kinase C as a therapeutic target.

The recognition of protein kinase C (PKC) as the long soughtafter receptor for the tumor-promoting phorbol esters established the potential role of PKC in carcinogenesis and as a potentially important target for cancer therapeutics (1, 2). PKC is a family of serine/threonine kinases that regulate a variety of cell functions including proliferation, gene expression, cell cycle, differentiation, ...

C-REACTIVE PROTEIN RESPONSE IN ANGINA PECTORIS

C-reactive protein (CRP) response was studied in 44 patients with acute angina pectoris admitted to the coronary care unit. 71 % of patients with acute myocardial infarction (MI)had positive CRP test while 73% of patients presumed to have unstable angina pectoris had negative CRP test. This test can be helpful in differentiating between acute MI and unstable angina pectoris.

Protein kinase C in heart failure: a therapeutic target?

Heart failure (HF) afflicts about 5 million people and causes 300,000 deaths a year in the United States alone. An integral part of the pathogenesis of HF is cardiac remodelling, and the signalling events that regulate it are a subject of intense research. Cardiac remodelling is the sum of responses of the heart to causes of HF, such as ischaemia, myocardial infarction, volume and pressure over...

High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome

Acute minor ischemic stroke and transient ischemic attack (TIA) are common, and patients with recent stroke or TIA are at high risk for subsequent stroke. It is estimated that 10% to 20% of these patients have a stroke within 3 months after the index event, most of which even occur within the first 2 days. Though several clinical risk factors have been reported to be associated with recurrent s...